Claims for Patent: 7,696,206

Summary for Patent: 7,696,206

Title:	2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
Abstract:	The application claims a compound of the formula ##STR00001## or a salt, a hydrate, or a hydrate of a salt thereof. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of erectile dysfunction.
Inventor(s):	Niewohner; Ulrich (Wermelskirchen, DE), Niewohner, legal representative; Maria (Wermelskirchen, DE), Es-Sayed; Mazen (Langenfeld, DE), Haning; Helmut (Wuppertal, DE), Schenke; Thomas (Bergisch Gladbach, DE), Schlemmer; Karl-Heinz (Wuppertal, DE), Keldenich; Jorg (Wuppertal, DE), Bischoff; Erwin (Wuppertal, DE), Perzborn; Elisabeth (Wuppertal, DE), Dembowsky; Klaus (Boston, MA), Serno; Peter (Bergisch Gladbach, DE), Nowakowski; Marc (Wuppertal, DE)
Assignee:	Bayer Schering Pharma Aktiengesellschaft (Berlin, DE)
Application Number:	12/569,720
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,696,206
Patent Claims:	1. A compound of the formula: ##STR00413## or a salt, a hydrate, or a hydrate of a salt thereof. 2. The compound according to claim 1 having the chemical name 2-[2-ethoxy-5-(4-ethyl-piperazine-1-sulphonyl)-phenyl]-5-methyl-7-propyl-- 3H-imidazo[5,1-f][1,2,4]triazin-4-one hydrochloride. 3. The compound according to claim 1 having the chemical name 2-[2-ethoxy-5-(4-ethyl-piperazine-1-sulphonyl)-phenyl]-5-methyl-7-propyl-- 3H-imidazo[5,1-f][1,2,4]triazin-4-one hydrochloride trihydrate. 4. A pharmaceutical composition comprising a compound according to claim 1 and a pharmacologically acceptable formulating agent. 5. A method of treating erectile dysfunction comprising administering to a mammal an effective amount of a compound according to claim 1. 6. The method of treating erectile dysfunction according to claim 5 wherein the mammal is a human.